Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Whitehall-Robins Chap Stick Labeling Exemption Request Denied

This article was originally published in The Tan Sheet

Executive Summary

FDA will not grant labeling exemptions based solely on financial considerations, the agency states in a Sept. 18 letter to Whitehall-Robins denying the company's request for an exemption from the OTC labeling final rule for three Chap Stick Flava-Craze skin protectant lip balm SKUs.

You may also be interested in...



AHP Dimetapp, Robitussin PPA Withdrawals Lead To $80 Mil. Charge In 2000

American Home Products recorded an $80 mil. charge in the fourth quarter due to its removal of eight Dimetapp products and one Robitussin item in response to data linking phenylpropanolamine with hemorrhagic stroke, the company said Jan. 25.

AHP Dimetapp, Robitussin PPA Withdrawals Lead To $80 Mil. Charge In 2000

American Home Products recorded an $80 mil. charge in the fourth quarter due to its removal of eight Dimetapp products and one Robitussin item in response to data linking phenylpropanolamine with hemorrhagic stroke, the company said Jan. 25.

AHP Dimetapp, Robitussin PPA Withdrawals Lead To $80 Mil. Charge In 2000

American Home Products recorded an $80 mil. charge in the fourth quarter due to its removal of eight Dimetapp products and one Robitussin item in response to data linking phenylpropanolamine with hemorrhagic stroke, the company said Jan. 25.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS091761

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel